Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

BACKGROUND: Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC) patients at present do not benefit from this treatment. The primary sit...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfieri, Roberta R, Galetti, Maricla, Tramonti, Stefano, Andreoli, Roberta, Mozzoni, Paola, Cavazzoni, Andrea, Bonelli, Mara, Fumarola, Claudia, La Monica, Silvia, Galvani, Elena, De Palma, Giuseppe, Mutti, Antonio, Mor, Marco, Tiseo, Marcello, Mari, Ettore, Ardizzoni, Andrea, Petronini, Pier Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281800/
https://www.ncbi.nlm.nih.gov/pubmed/22111840
http://dx.doi.org/10.1186/1476-4598-10-143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281800/
https://www.ncbi.nlm.nih.gov/pubmed/22111840
http://dx.doi.org/10.1186/1476-4598-10-143

Ejemplares similares